Current treatments in the management of idiopathic pulmonary fibrosis: Pirfenidone and nintedanib

Clinical Medicine Insights: Therapeutics

Volumn 9, Issue , 2017, Pages

  Hayton, Conal ^a   Chaudhuri, Nazia ^b  

^a NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antifibrotic; Idiopathic pulmonary fibrosis; Interstitial lung disease; Nintedanib; Pirfenidone

Indexed keywords

NINTEDANIB; PIRFENIDONE;

DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; PATIENT PREFERENCE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; THERAPY;

EID: 85045020247     PISSN: None     EISSN: 1179559X     Source Type: Journal    
DOI: 10.1177/1179559X17719126     Document Type: Review

References (35)

1. Richeldi L, Ferrara G, Davies HR, Franco F. Corticosteroids for idiopathic pulmonary fibrosis (Cochrane Review). Cochrane Database Syst Rev. 2003;3: CD002880.
2. Davies HR, Richeldi L, Walters EH. Immunomodulatory agents for idiopathic pulmonary fibrosis (Cochrane Review). Cochrane Database Syst Rev. 2003;3: CD003134.
3. Idiopathic Pulmonary Fibrosis Clinical Research Network; Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366: 1968-1977.
4. Raghu G, Nyberg F, Morgan G. The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer. 2004;91:S3-S10.
5. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824.
6. Lawson WE, Loyd JE. The genetic approach in pulmonary fibrosis: can it provide clues to this complex disease? Proc Am Thorac Soc. 2006;3:345-349.
7. Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for pulmonary fibrosis. Am J Respir Crit Care Med. 1997;155:242-248.
8. Hutchinson J, Fogarty A, Hubbard R, McKeever T. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J. 2015;46:797-806.
9. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;157:199-203.
10. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353:2229-2242.
11. Peikert T, Daniels CE, Beebe TJ, Meyer KC, Ryu JH. Assessment of current practice in the diagnosis and therapy of idiopathic pulmonary fibrosis. Respir Med. 2008;102:1342-1348.
12. Kaneko M, Inoue H, Nakazawa R, et al. Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts. Clin Exp Immunol. 1998;113:72-76.
13. Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol. 2008;590: 400-408.
14. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040-1047.
15. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:821-829.
16. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377:1760-1769.
17. National Institute for Health and Care Excellence (NICE). Pirfenidone for Treating Idiopathic Pulmonary Fibrosis (TA282). London, England: NICE; 2013.
18. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370:2083-2092.
19. Nathan SD, Albera C, Bradford WZ, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2017;5:33-41.
20. Genentech USA, Inc. Prescribing information for ESBRIET. https://www.gene.com/download/pdf/esbriet_prescribing.pdf. Published 2017. Accessed January 17, 2017.
21. Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1434-1445.
22. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071-2082.
23. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079-1087.
24. National Institute for Health and Care Excellence (NICE). Nintedanib for Treating Idiopathic Pulmonary Fibrosis. (TA379). London, England: NICE; 2016
25. Kolb M, Richeldi L, Behr J, et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 2017;72:340-346.
26. Boehringer Ingelheim Pharma. Ofev summary of product characteristics. https://products.boehringer-ingelheim.com/ofev/sites/default/files/OFEVSMPC.pdf. Published 2015. Accessed January 17, 2017.
27. Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis: an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192:e3-e19.
28. Ikeda S, Sekine A, Baba T, et al. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report. BMC Pulm Med. 2016;16:38.
29. Hagmeyer L, Treml M, Priegnitz C, Randerath WJ. Successful concomitant therapy with pirfenidone and nintedanib in idiopathic pulmonary fibrosis: a case report. Respiration. 2016;91:327-332.
30. Sakamoto S, Muramatsu Y, Satoh K, et al. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study. Respirology. 2015;20:445-452.
31. Behr J, Bendstrup E, Crestani B, et al. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2016;4:445-453.
32. Kreuter M, Wuyts W, Renzoni E, et al. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med. 2016;4:381-389.
33. Shulgina L, Cahn AP, Chilvers ER, et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax. 2013;68:155-162.
34. Raghu G, Brown KK, Collard HR, et al. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. Lancet Respir Med. 2017;5:22-32.
35. Raghu G, Scholand MB, de Andrade J, et al. FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis. Eur Respir J. 2016;47:1481-1491.